TASIMELTEON

Pharmaceutical preparations containing (1R, 2R)-N-2-(2,3-Dihydrobenzofuran-4-yl)-cyclopropylmethylpropanamide, for the treatment or prevention of diseases of angiogenesis, diabetic retinopathy and diabetic macular edema, neurodegeneration, inflammation and cancer, depressive disorders, autism, and sleep disorders